FIG 4.

Synergistic effect of colistin (CST) combined with 3PO, PFK-015, or PFK-158 in vivo. (A to F) Mice were intraperitoneally infected with HLCR clinical isolate E. cloacae D01 (A to C) or K. pneumoniae H04 (D to F). A total of 15 mg/kg 3PO (A and D), PFK-015 (B and E), or PFK-158 (C and F), alone or combined with colistin, was intravenously injected at 1 h postinfection (n = 10 per group). A solvent was injected into the model group. (G) Bacterial loads in organs (liver, spleen, and kidney) influenced by colistin, PFK-158, or combination therapy in the E. cloacae D01 infection model were determined at 16 h postinfection (n = 8 per group). *, P ≤ 0.05; ****, P ≤ 0.0001 (compared with the model group).